Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - H.C. Wainwright has reiterated its Buy rating and $100.00 price target on Korro Bio Inc. (NASDAQ:KRRO), following the company’s announcement of European orphan drug designation for its lead candidate. According to InvestingPro data, analyst targets range from $25 to $180, with the stock currently trading at $13.34, significantly below its 52-week high of $98.
The European Medicines Agency (EMA) Committee adopted a positive opinion on KRRO-110, Korro Bio’s investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), granting it orphan drug designation status in the European Union.
This European designation follows the FDA’s Orphan Drug Designation for KRRO-110 in March 2025, providing Korro Bio with development incentives including protocol assistance, reduced regulatory fees, and market exclusivity upon approval.
KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD, with an interim readout expected in the second half of 2025, according to the research firm.
The EMA grants orphan designation to medicines intended for treating life-threatening or chronically debilitating diseases affecting fewer than five in every 10,000 people in the European Union, provided the medicine offers significant benefit to patients.
In other recent news, Korro Bio has been granted orphan drug designation by the European Medicines Agency for its investigational treatment, KRRO-110, aimed at Alpha-1 Antitrypsin Deficiency. This follows a similar designation by the U.S. FDA earlier this year, with the treatment currently undergoing Phase 1/2a clinical trials. Meanwhile, H.C. Wainwright has adjusted its financial outlook for Korro Bio, lowering the 12-month price target from $115 to $100, though it maintains a Buy rating. The adjustment reflects anticipated regulatory challenges in the genetic medicines sector, particularly with new leadership at the FDA’s Center for Biologics.
Additionally, Cantor Fitzgerald has initiated coverage of Korro Bio with an Overweight rating and a price target of $74. The firm highlights Korro’s potential in RNA editing oligonucleotide therapeutics and emphasizes the promise of KRRO-110 in treating Alpha-1 Antitrypsin Deficiency. Cantor Fitzgerald also notes the competitive landscape of AATD and suggests that Korro’s treatment could be a leading option. The firm anticipates further developments in Korro’s clinical programs, possibly targeting conditions like Phenylketonuria. These updates reflect the evolving landscape for Korro Bio as it navigates regulatory and market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.